[1] Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016; 4: 256. doi: 10.21037/atm.2016.06.33 [2]

[Report on cardiovascular health and disease in China 2019]. Journal of Cardiovascular and Pulmonary Diseases 2019; 39: 1145-1156. [Article in Chinese].

[3]

Sheng-Shou HU, Run-Lin GAO, Li-Sheng LIU, et al. [Synopsis of China cardiovascular disease report 2018]. Chinese Circulation Journal 2019; 34: 209-220. [Article in Chinese].

[4] Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 2018; 391: 41−50. doi: 10.1016/S0140-6736(17)32713-7 [5] Fanaroff AC, Zakroysky P, Wojdyla D, et al. Relationship between operator volume and long-term outcomes after percutaneous coronary intervention. Circulation 2019; 139: 458−472. doi: 10.1161/CIRCULATIONAHA.117.033325 [6]

Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-related adverse events > 1 year after percutaneous coronary intervention. J Am Coll Cardiol 2020; 75: 590−604.

[7] Latib A, Ielasi A, Ferri L, et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen. Int J Cardiol 2013; 165: 444−447. doi: 10.1016/j.ijcard.2011.08.080 [8]

Ge JB, Fan WH, Zhou JM, et al. Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial. Chin Med J (Engl) 2020; 134: 185−192.

[9]

Wang SL, Wang CL, Wang PL, et al. Combination of Chinese herbal medicines and conventional treatment versus conventional treatment alone in patients with acute coronary syndrome after percutaneous coronary intervention (5C trial): an open-label randomized controlled, multicenter study. Evid Based Complement Alternat Med 2013; 2013: 741518.

[10] Guo M, Wang P, Du J, et al. Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial. Pharmacol Res 2020; 158: 104883. doi: 10.1016/j.phrs.2020.104883 [11]

Wang L, Zhao X, Mao S, et al. Efficacy of Danlou tablet in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from a multicentre, placebo-controlled, randomized trial. Evid Based Complement Alternat Med 2016; 2016: 7960503.

[12]

Zhao S, Tang Y, Cai H, et al. Treatment of Danhong injection combined with naoxintong capsule in acute coronary syndrome patients undergoing PCI operation: study for a randomized controlled and double-blind trial. Evid Based Complement Alternat Med 2018; 2018: 8485472.

[13]

Wu HL, Wang YF, Li JZ, et al. A multi-centre randomized clinical trial on efficacy and safety of Huxin formula in patients undergoing percutaneous coronary intervention. Evid Based Complement Alternat Med 2014; 2014: 143064.

[14]

Li C, Li Q, Xu J, et al. The efficacy and safety of compound danshen dripping pill combined with percutaneous coronary intervention for coronary heart disease. Evid Based Complement Alternat Med 2020; 2020: 5067137.

[15]

Zheng GH, Liu JP, Chu JF, et al. Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease. Cochrane Database Syst Rev 2013; 5: CD009581.

[16]

Mao C, Fu XH, Yuan JQ, et al. Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention. Cochrane Database Syst Rev 2015; 5: CD010237.

[17]

Chinese expert consensus on antiplatelet therapy. Chinese Journal of Cardiology 2013: 183-194.

[18] Duan WH, Lu F, Li LZ, et al. Clinical efficacy of traditional Chinese medicine on acute myocardial infarction: a prospective cohort study. Chin J Integr Med 2012; 18: 807−812. doi: 10.1007/s11655-012-1116-9 [19] Gao ZY, Xu H, Shi DZ, et al. Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. J Ethnopharmacol 2012; 141: 578−583. doi: 10.1016/j.jep.2011.08.071 [20]

Yamamoto MH, Maehara A, Stone GW, et al. Two-year outcomes after stenting of lipid-rich and non-rich coronary plaques. J Am Coll Cardiol 2020; 75: 1371−1382.

[21] Rha SW, Choi BG, Choi SY, et al. Multicenter experience with percutaneous coronary intervention for chronic total occlusion in Korean population: analysis of the Korean nationwide multicenter chronic total occlusion registry. Coron Artery Dis 2020; 31: 319−326. doi: 10.1097/MCA.0000000000000838 [22] Plitt A, Claessen BE, Sartori S, et al. Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheter Cardiovasc Interv 2020; 96: 558−564. doi: 10.1002/ccd.28488 [23] Beyhoff N, Cao D, Mehran R, et al. Prognostic impact of high-sensitivity C-reactive protein in patients undergoing percutaneous coronary intervention according to BMI. JACC Cardiovasc Interv 2020; 13: 2882−2892. doi: 10.1016/j.jcin.2020.09.024 [24] Zeng Z, Zhuang Z, He Y, et al. Efficacy and safety of Shen-Song-Yang-Xin capsule for treating arrhythmia in the elderly patients with coronary heart disease: Protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97: e13599. doi: 10.1097/MD.0000000000013599 [25] Zhang KJ, Zhu JZ, Bao XY, et al. Shexiang Baoxin pills for coronary heart disease in animal models: preclinical evidence and promoting angiogenesis mechanism. Front Pharmacol 2017; 8: 404. doi: 10.3389/fphar.2017.00404 [26]

Guo CX, Li ZY, Niu JB, et al. Qishen capsule safely boosts cardiac function and angiogenesis via the MEK/ERK pathway in a rat myocardial infarction model. J Geriatr Cardiol 2019; 16: 764−774.

[27] Chen G, Xu C, Gillette TG, et al. Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury. Theranostics 2020; 10: 11754−11774. doi: 10.7150/thno.43163 [28] Aa N, Guo JH, Cao B, et al. Compound Danshen dripping pills normalize a reprogrammed metabolism of myocardial ischemia rats to interpret its time-dependent efficacy in clinic trials: a metabolomic study. Metabolomics 2019; 15: 128. doi: 10.1007/s11306-019-1577-3